Dupilumab attenuates the expression of TSLP and IL-8 induced by dsRNA and IL-4/IL-13 co-stimulation in human small airway epithelial cells.

Dupilumab attenuates TSLP and IL-8 expression induced by co-stimulation with dsRNA and IL-4 Dupilumab pretreatment (10–1000 ng/mL) showed a trend toward reducing TSLP gene expression induced by co-stimulation with IL-4 and dsRNA (relative TSLP expression: IL-4 + dsRNA group, 1.893 ± 478.1; dupilumab 10, 100, and 1000 ng/mL groups, 1.779 ± 313.2, 1.700 ± 225.8, and 1.669 ± 568.7, respectively).

also in 53,322 other papers

The greatest reduction in both TSLP and IL-8 gene expression was observed with the highest dupilumab concentration (1000 ng/mL), although these reductions did not reach statistical significance.

also in 111,027 other papers